Document is current
Any future updates will be listed below
-
Authors
Espinosa, Enrique https://orcid.org/0000-0001-6562-7902
Berciano-Guerrero, Miguel-Ángel
Muñoz-Couselo, Eva
Puértolas, Teresa
Manzano, José Luis
Soria, Ainara
de Miguel, Pablo Ayala
Crespo, Guillermo
Sanz, Lourdes Gutiérrez
Cerezuela-Fuentes, Pablo
de la Rosa, Carlos Aguado
Majem, Margarita
Castaño, Almudena García
Berrocal, Alfonso
Arroyo, Francisco Ramon García
de la Borbolla, María Rodríguez
Bellido, Lorena
Martínez, Javier Medina
Fernández, Luis Antonio
Carnicero, Alfonso Martin
Castro, Rafael López
Rodríguez, Aida Bujosa
Lecumberri, Mª José
Guzmán, José Carlos Villa
Balea, Begoña Campos
Rodríguez, Joaquín Fra
Bautista, Javier Valdivia
Pérez, Victor Navarro
Mujika, Karmele
Subias, Mónica Corral
Hernández, Berta
Algarra, Salvador Martín
Márquez-Rodas, Iván
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03605771 at ClinicalTrials.govDocuments that mention this clinical trial
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.
https://doi.org/10.1200/jco.2023.41.16_suppl.9547
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
https://doi.org/10.1007/s12094-025-04098-3
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801
https://doi.org/10.1007/s12094-025-04164-w
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801.
https://doi.org/10.1200/jco.2024.42.16_suppl.e21515
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)
https://doi.org/10.1007/s12094-025-04005-w
-
Funding
Funding for this research was provided by:
Universidad Autónoma de Madrid
- License Information
-
More Information
Article History
Received: 12 March 2025
Accepted: 13 October 2025
First Online: 28 November 2025
Declarations
:
: GC has received honoraria as consultancy from BMS and Pierre Fabre, and speaking grants and travel/accommodation expenses from Regeneron, BMS, Roche, Pierre Fabre, MSD and Novartis. RLC: No conflicts of interest related to this paper. FRGA: No conflicts of interest related to this paper. KM: No conflicts of interest related to this paper. ABR: No conflicts of interest related to this paper. LBH: No conflicts of interest related to this paper. The remaining co-authors have no conflicts of interest to be declared regarding this paper.
: The M&M section states that patients provided consent to participate. This was mandatory to be included in the GEM1801 study.
